Research note: Immunotherapy may also target glioblastomas, study shows

Glioblastomas, a deadly form of brain cancer, may be yet another cancer that responds to immunotherapy, a new Yale-led study suggests. An analysis of brain tissue from glioblastoma patients shows immune system response to tumors was strengthened when exposed to immunotherapy drug currently used to treat melanoma. So-called anti-PD1 therapy has improved outcomes in a variety of cancer types and will now be tested on glioblastoma patients in Phase III trials, said Dr. David Hafler, the William S. and Lois Stiles Edgerly Professor of Neurology, chair of neurology and senior author of the research.  The results were reported online April 20 in The Journal of Clinical Investigation.


Read the article in The Journal of Clinical Investigation